Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Desp...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Leonetti, Alessandro, Sharma, Sugandhi, Minari, Roberta, Perego, Paola, Giovannetti, Elisa, Tiseo, Marcello
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2019
Témata:
Review Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6889286/
https://ncbi.nlm.nih.gov/pubmed/31564718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0573-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky